Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 814-217-0 | CAS number: 353258-35-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vivo
Administrative data
- Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 018
- Report date:
- 2018
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 474 (Mammalian Erythrocyte Micronucleus Test)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.5395 (In Vivo Mammalian Cytogenetics Tests: Erythrocyte Micronucleus Assay)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.12 (Mutagenicity - In Vivo Mammalian Erythrocyte Micronucleus Test)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: JMAFF 2-1-19-3 (2000)
- Deviations:
- no
- GLP compliance:
- yes
- Type of assay:
- mammalian erythrocyte micronucleus test
Test material
- Reference substance name:
- 8-chloro-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxylic acid
- Cas Number:
- 353258-35-2
- Molecular formula:
- C9H4ClF3N2O2
- IUPAC Name:
- 8-chloro-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxylic acid
1
- Specific details on test material used for the study:
- Test Substance: IN-QEK31-011
Lot Number: SG0312574
Purity: 98.2%
Test animals
- Species:
- mouse
- Strain:
- other: Crl:CD1(ICR)
- Details on species / strain selection:
- Mice have been shown to exhibit micronuclei indicative of broken chromosomes (clastogenic effects) or spindle effects (aneugenic effects) in response to known mutagens and were therefore used in this assay. The Crl:CD1(ICR) mouse was selected based on extensive experience with this strain at test facility and its suitability for genetic toxicology studies.
- Sex:
- male/female
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- 0.1% Tween-80 in 0.5% aqueous methylcellulose
- Frequency of treatment:
- Single dose
- Post exposure period:
- Approximately 48 and 72 hours after dose administration, peripheral blood samples were collected for micronucleus evaluation.
Doses / concentrationsopen allclose all
- Dose / conc.:
- 500 mg/kg bw/day
- Dose / conc.:
- 1 000 mg/kg bw/day
- Dose / conc.:
- 1 300 mg/kg bw/day
- Dose / conc.:
- 1 600 mg/kg bw/day
- Remarks:
- not analyzed due to excessive mortality
- Dose / conc.:
- 2 000 mg/kg bw/day
- Remarks:
- not analyzed due to excessive mortality
- No. of animals per sex per dose:
- Pre test: 3/sex/group
Main study: 5/sex/group (0, 500, 1000 mg/kg bw and positive control); 7/sex (2000 mg/kg bw)
Follow-up study: 5/sex (vehicle control); 7/sex/group (1300 and 1600 mg/kg bw) - Control animals:
- yes, concurrent vehicle
- Positive control(s):
- Cyclophosphamide (CP), the positive control substance, was prepared in deionized water and administered once orally by gavage at a dose of 30 mg/kg and a dose volume of 10 mL/kg.
Examinations
- Tissues and cell types examined:
- Peripheral blood and micronucleated RET
- Evaluation criteria:
- Providing that all valid test criteria were fulfilled, a test substance was considered clearly negative if, in all experimental conditions examined:
• None of the treatment groups exhibited a statistically significant increase in the frequency of MN RETs compared with the concurrent negative control,
• There was no dose-related increase at any sampling time when evaluated by an appropriate trend test,
• All results (group means) were inside the distribution of the historical negative control data (e.g., Poisson-based 95% control limits), and
• Bone marrow exposure to the test substance occurred (as evident by either a reduction in the RET frequency, measurement of the test substance levels in plasma or blood, or ADME data obtained in an independent study).
Providing that all valid test criteria were fulfilled, a test substance was considered clearly positive if:
• At least one of the treatment groups exhibited a statistically significant increase in the frequency of MN RETs compared with the concurrent negative control,
• This increase was dose-related at least at one sampling time when evaluated with an appropriate trend test, and
• Any of these results were outside the distribution of the historical negative control data (e.g., Poisson-based 95% control limits).
If only the highest dose was examined at a particular sampling time, a test substance was considered clearly positive if there was a statistically significant increase compared with the concurrent negative control and the results were outside the distribution of the historical negative control data (e.g., Poisson-based 95% control limits). When conducting a dose-response analysis, at least 3 treated dose groups should have been analyzed. Statistical tests should have used the animal as the experimental unit. - Statistics:
- Male and female animals were evaluated separately. The frequency of RETs was evaluated for a decreasing response while the frequency of MN RETs was evaluated for an increasing response. For each sex and timepoint, an analysis of variance (ANOVA) and Dunnett’s test were performed on both the RET and MN RET frequencies. Where the data were found not consistent with the requirements for a Dunnett’s test, a Dunn’s non-parametric test was used. A t-test was used to compare positive and negative controls. Statistical significance was further evaluated for a dose response using the Williams’s test or the non-parametric Jonckheere-Terpstra test, where appropriate.
No statistical analysis was conducted on body weights or clinical signs
Results and discussion
Test results
- Key result
- Sex:
- male/female
- Genotoxicity:
- negative
- Toxicity:
- yes
- Remarks:
- In the main study, signs of toxicity were observed in both male and female mice at 2000 mg/kg. Clinical observations included lethargy, eyelid ptosis, dehydration, labored breathing, ataxia, abnormal gate, discharge, prostration, moribundity, and death.
- Vehicle controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- Clinical Observations and Mortality
No clinical signs of toxicity were observed in the range finding study conducted at 2000 mg/kg bw.
In the main micronucleus study clinical signs of toxicity were observed in both male and female mice at 2000 mg/kg bw. Clinical observations included lethargy (2/7 males and 1/7 females), eyelid ptosis (1/7 males), dehydration (2/7 males and 1/7 females), labored breathing (2/7 males and 1/7 females), ataxia (1/7 males), abnormal gate (1/7 males), discharge (1/7 females), prostration (1/7 females), moribundity (2/7 males and 1/7 females), and death (3/7 males and 1/7 females). The moribund animals were all removed from study on test day 2. The four animals in which death occurred were found dead on test day 3. Due to this excessive toxicity, all remaining mice in the 2000 mg/kg bw dose group were humanely sacrificed on test day 3 without blood collection.
In the follow-up micronucleus study no clinical signs of toxicity were observed; however, several mice were found dead. At 1600 mg/kg bw 3/7 male mice were found dead (two on test day 2 and one on test day 3) and 2/7 female mice were found dead (one on test days 2 and 3 each). At 1300 mg/kg bw 2/7 male mice were found dead on day test day 2.
It is believed that the reason moribundity/mortality were observed in both the main and follow-up studies but not the range finding study was the difference in the formulation procedure, where bead milling of the test substance formulation may have increased bioavailability.
Applicant's summary and conclusion
- Conclusions:
- Test substance was negative in this in vivo Mouse Micronucleus study
- Executive summary:
The test substance was evaluated for its ability to induce micronuclei in bone marrow by analyzing peripheral blood reticulocytes (RETs) in male and female Crl:CD1(ICR) mice according to the guidelines OECD 474, US EPA OPPTS 870.5395, EC B.12 and JMAFF. Based on range-finding results, doses of 500, 1000, and 2000 mg/kg body weight (bw) of the test substance were selected for the main micronucleus study. Concurrent control groups were administered 0.1% Tween-80 in 0.5% aqueous methylcellulose as the vehicle (negative) control, or 30 mg/kg bw of cyclophosphamide (positive control). However, in the main study 2000 mg/kg bw was found to be above the maximum tolerated dose (MTD), while no clinical signs of toxicity were observed at 500 or 1000 mg/kg bw. Therefore, a follow-up micronucleus study was conducted with animals administered a single dose of the test substance at 1300 or 1600 mg/kg bw, or the vehicle control.
All animals were given a single dose by oral gavage. The vehicle control, 500 and 1000 mg/kg bw dose groups, and the positive control groups contained 5 animals/sex. The 1300, 1600, and 2000 mg/kg bw group contained 7 animals/sex. Peripheral blood samples were collected via tail vein bleeding, and a micronucleus evaluation was conducted by flow cytometry. The samples were collected approximately 48 and 72 hours post-dosing for the test substance treated and vehicle control groups, and approximately 48 hours post-dosing for the positive control group. A total of 20,000 RETs were analyzed per blood sample for the induction of micronuclei and toxicity as indicated by the frequency of immature erythrocytes (% RETs) among total erythrocytes (i.e., RETs plus normochromatic erythrocytes, NCEs). All surviving animals were weighed and observed for mortality and clinical signs of toxicity at least daily.
The formulated test substance formed a suspension in all studies. However, based on the range finding study the formulations for the main and follow-up studies were bead milled to increase homogeneity at all dose levels. Aliquots of the vehicle control and each test substance concentration were taken to confirm homogeneity, dose concentrations, and stability. Homogeneity and target concentrations were verified, and the test substance was stable for the duration of the dosing period.
No clinical signs of toxicity were observed in the range finding study conducted at 2000 mg/kg bw.
In the main micronucleus study clinical signs of toxicity were observed in both male and female mice at 2000 mg/kg bw. Clinical observations included lethargy (2/7 males and 1/7 females), eyelid ptosis (1/7 males), dehydration (2/7 males and 1/7 females), labored breathing (2/7 males and 1/7 females), ataxia (1/7 males), abnormal gate (1/7 males), discharge (1/7 females), prostration (1/7 females), moribundity (2/7 males and 1/7 females), and death (3/7 males and 1/7 females). On test day 3 all the remaining mice in the 2000 mg/kg bw dose group were humanely sacrificed without blood collection.
In the follow-up micronucleus study no clinical signs of toxicity were observed; however, several mice were found dead. At 1600 mg/kg bw 3/7 male and 2/7 female mice died. At 1300 mg/kg bw 2/7 male mice died.
It is believed that the reason clinical observations and moribundity/mortality were observed in the main and follow-up study but not the range finding study was the difference in the formulation procedure, where bead milling of the test substance formulation may have increased bioavailability.
No abnormalities were detected in the vehicle or positive control groups.
Samples from the negative control, positive control, 500, 1000, and 1300 mg/kg bw dose group were analyzed at the 48-hour time point. At the 72-hour time point only samples from the negative control and 1300 mg/kg bw dose group were analyzed. Main study negative control, 500, and 1000 mg/kg bw dose groups were not analyzed at the 72-hour time point since no positive response was observed for the 1300 mg/kg bw dose group. The 1600 mg/kg bw dose group was not analyzed at either time point due to excessive mortality.
No statistically significant or biologically relevant increases in the micronucleated RET frequency were observed in any evaluated test substance treated group of male or female animals at either time point.
Statistically significant reductions in %RETs were observed with male mice in the 500 and 1000 mg/kg bw dose groups at the 48-hour time point and in the 1300 mg/kg bw dose group at the 72-hour time point. However, there was no reduction in %RETs observed in the 1300 mg/kg bw dose group at 48 hours and there were no statistically significant decreases in %RETs among the total erythrocytes observed with female mice at either time point at any dose group. Therefore, these reductions were not considered as sufficient evidence of target cell exposure.
Target cell exposure was evaluated in an independent study. The results of this study indicate that the systemic exposure in the male and female mice was evident based on the presence of quantifiable test substance in pooled plasma samples at 4 hours after a single oral gavage administration at a dose level of 500 mg/kg bw.
As expected, statistically significant increases in MN-RET frequency were found in CP-treated animals of both sexes. Statistically significant depressions in RET frequency were observed in both male and female animals administered CP, indicating that the 30 mg/kg bw dose level was sufficient to induce toxicity as well as induce MN-RETs.
All criteria for a valid study were met. Under the conditions of this study, test substance did not induce increases in micronucleated RETs in mouse peripheral blood. The test substance was concluded to be negative in this in vivo study.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.